Tag: C5a receptor antagonist

Unlike many brand-name medications, the active ingredient avacopan is its own generic name, sold exclusively under the brand name Tavneos since its FDA approval in 2021. It is used to treat severe, active ANCA-associated vasculitis, offering a targeted approach to reduce inflammation and potentially lower dependency on high-dose steroids.

In a pivotal clinical trial, 65.7% of participants treated with Tavneos achieved sustained remission of ANCA-associated vasculitis symptoms at 52 weeks, a significantly higher rate than the standard treatment arm. For adults managing severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), understanding what are the benefits of taking Tavneos is crucial for considering this targeted therapy.